Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan

International Journal of Clinical Oncology

Volumn 16, Issue 5, 2011, Pages 560-567

  Nagai, Hiroki ^a,b   Tanaka, Shiro ^a   Niimi, Miyuki ^a   Seo, Nanae ^a   Sasaki, Takahiko ^a,c   Date, Hiroshi ^b   Mishima, Michiaki ^b   Yasuda, Hiroyasu ^a,d   Yanagihara, Kazuhiro ^a,b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

Adverse events; Epidermal growth factor receptor; Epidermal growth factor receptor tyrosine kinase inhibitor; Erlotinib; Japanese outpatients; Non small cell lung cancer

Indexed keywords

ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GAIT DISORDER; HAND FOOT SYNDROME; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LUNG NON SMALL CELL CANCER; MALE; MUSCLE WEAKNESS; NAUSEA; OUTPATIENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; STOMATITIS; TASTE DISORDER; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; OUTPATIENTS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84857098148     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0228-0     Document Type: Article

References (15)

1. Mendelsohn J (1997) Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3:2703-2707 (Pubitemid 28133130)
2. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537 (Pubitemid 41540110)
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
4. Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831-3837 (Pubitemid 46630729)
5. Yamamoto N, Horiike A, Fujisaka Y et al (2008) Phase I dosefinding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489-496 (Pubitemid 350275984)
6. Kubota K, Nishiwaki Y, Tamura T et al (2008) Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 3:1439-1445
7. Ando M, Okamoto I, Yamamoto N et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549-2556 (Pubitemid 46630633)
8. Yoshida K, Yatabe Y, Park JY et al (2007) Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2:22-28 (Pubitemid 47163924)
9. Cohen MH, Williams GA, Sridhara R et al (2004) United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218 (Pubitemid 38365209)
10. Li J, Zhao M, He P et al (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzyme. Clin Cancer Res 13:3731-3737 (Pubitemid 46955138)
11. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
12. CTCAE. http://ctep.cancer.gov/forms/CTCAEv3.pdf
13. Yamamoto K, Matsumoto S, Tada H et al (2008) A data capture system for outcomes studies that integrates with electronic health records: development and potential uses. J Med Syst 32:423-427
14. Uhm JE, Park BB, Ahn MJ et al (2009) Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol 4:1136-1143
15. Weatley-Price P, Ding K, Seymour L et al (2008) Erlotinib for advanced non-small cell lung cancer in the elderly: an analysis of the national cancer institute of Canada Clinical Trial Group Study BR.21. J Clin Oncol 26:2350-2357